Related Experiment Video
Updated: Jun 3, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Novel drug delivery systems for glaucoma.
1Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA. erin.lavik@case.edu
Eye (London, England)
|April 9, 2011
Summary
Novel drug delivery systems for glaucoma aim to improve patient adherence and treatment efficacy. These advanced methods, including implants and injectables, offer sustained intraocular pressure (IOP) reduction and potential neuroprotection.
Area of Science:
- Ophthalmology
- Pharmaceutics
- Biomaterials
Background:
- Glaucoma treatment traditionally relies on reducing intraocular pressure (IOP) via eye drops.
- Poor patient adherence to eye drop regimens compromises clinical efficacy.
- Existing treatments necessitate improved delivery methods for sustained IOP control.
Purpose of the Study:
- To review current and emerging drug delivery systems for glaucoma management.
- To explore technologies enhancing patient adherence and therapeutic outcomes.
- To discuss the potential of novel systems for sustained IOP reduction and neuroprotection.
Main Methods:
- Review of literature on pharmaceutical and surgical glaucoma treatments.
- Analysis of novel drug delivery systems: contact lenses, injectables (micro/nanoparticles), and implants.
- Evaluation of delivery systems for neuroprotective agents.
Main Results:
- Novel systems offer sustained IOP management for months, improving adherence.
- Injectable and implantable systems provide localized, sustained drug delivery.
- Development of delivery systems is crucial for neuroprotective agents targeting the retina and optic nerve.
Conclusions:
- Advanced drug delivery systems promise to enhance glaucoma treatment efficacy and patient adherence.
- These technologies offer potential for improved IOP control and neuroprotection, aiming to preserve sight.
- Future research should focus on optimizing delivery systems for both IOP reduction and neuroprotection.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...